

ANTIBIOTIC STEWARDSHIP PROGRAMS: A 15-YEAR REVIEW (2010–2026)

Nashra Afaq

Assistant Professor¹, Department of Microbiology and CRL, Rama Medical College Hospital and Research Centre, Uttar Pradesh, India.

, R. Sujatha

Professor and Head², Department of Microbiology, Rama Medical College Hospital and Research Centre, Uttar Pradesh, India.

Corresponding Author: Dr. R. Sujatha*

Email ID: drsujatha152rama@gmail.com

Abstract

Antimicrobial resistance (AMR) has emerged as a major global health threat over the past decades, largely driven by inappropriate antibiotic use. Antibiotic Stewardship Programs (ASPs) have been widely implemented since 2010 to optimize antimicrobial use, improve patient outcomes, and curb resistance. This review evaluates the evolution, implementation strategies, and outcomes of ASPs over the past 15 years (2010–2026). A structured literature review was conducted using major databases, focusing on clinical outcomes, antibiotic consumption, resistance patterns, and healthcare costs. Evidence consistently demonstrates that ASPs significantly reduce inappropriate antibiotic use, decrease resistance rates, lower healthcare costs, and improve patient safety. Despite notable success, challenges persist in low-resource settings, outpatient care, and global standardization. Strengthening multidisciplinary approaches, digital integration, and global policy frameworks is essential for the future of stewardship programs.

INTRODUCTION

Antimicrobial resistance (AMR) is a critical public health crisis responsible for increasing morbidity, mortality, and healthcare costs worldwide. The misuse and overuse of antibiotics have accelerated the emergence of resistant pathogens, necessitating urgent global interventions [1]. Antibiotic stewardship refers to coordinated interventions designed to improve and measure appropriate antibiotic use by optimizing drug selection, dose, duration, and route [2].

The concept of stewardship was first introduced in the 1990s, but it gained global attention after 2010 due to rising resistance trends and declining antibiotic development [1]. Studies estimate that **20–50% of antibiotic prescriptions are inappropriate**, particularly in hospital and long-term care settings [1]. This inappropriate usage has been linked to adverse outcomes, including *Clostridioides difficile* infections and increased mortality [3].

In response, organizations such as the **Centers for Disease Control and**

Prevention (CDC) and Infectious Diseases Society of America (IDSA) developed structured frameworks for ASP implementation. The CDC introduced the **Core Elements of Hospital Antibiotic Stewardship Programs in 2014**, later updated in 2019 and beyond [4]. These frameworks emphasize leadership commitment, accountability, drug expertise, action, tracking, reporting, and education.

Over the past 15 years, ASPs have expanded across healthcare systems, including hospitals, outpatient clinics, long-term care facilities, and even community and agricultural settings. This review aims to critically analyze the progress, effectiveness, and challenges of ASPs from 2010 to 2026.

MATERIALS AND METHODS

A narrative review was conducted following standard review methodology.

Search Strategy

A comprehensive search was performed in:

- PubMed/MEDLINE
- Scopus
- Cochrane Library
- Google Scholar

Keywords used:

- “Antibiotic stewardship program”
- “Antimicrobial stewardship”
- “antibiotic resistance”
- “ASP outcomes”
- “stewardship interventions”

Inclusion Criteria

- Studies published between **2010–2026**
- Clinical trials, systematic reviews, meta-analyses, and guidelines
- Studies evaluating ASP outcomes (clinical, microbiological, or economic)

Exclusion Criteria

- Non-English articles
- Studies before 2010
- Editorials without primary data

Data Extraction

Data extracted included:

- Study design
- ASP interventions
- Outcomes (antibiotic use, resistance, mortality, cost)

RESULTS

1. Reduction in Antibiotic Use

Multiple studies demonstrated significant reductions in antibiotic prescribing:

- ASPs reduced antibiotic prescriptions by **~10%** and overall consumption by **~28%** [5].
- Significant reductions were observed in high-risk antibiotics such as fluoroquinolones and carbapenems [5].

2. Improvement in Clinical Outcomes

- Reduced hospital stay duration

- Lower incidence of adverse drug reactions
- Decreased Clostridioides difficile infections [3]

3. Impact on Antimicrobial Resistance

- Improved bacterial susceptibility patterns
- Stabilization or reduction in resistant organisms in many settings [6]

4. Economic Benefits

- Reduced pharmacy costs
- Decreased hospitalization costs
- Efficient resource utilization [3]

5. Implementation Strategies

Common ASP interventions:

- Prospective audit and feedback
- Preauthorization of antibiotics
- IV-to-oral switch
- De-escalation therapy
- Clinical decision support systems [6]

DISCUSSION

Over the past 15 years, ASPs have evolved into a cornerstone of modern healthcare systems. Their effectiveness lies in structured, multidisciplinary approaches integrating clinicians, pharmacists, microbiologists, and infection control teams.

Effectiveness of ASPs

Evidence consistently shows that ASPs improve antibiotic utilization and patient outcomes. A systematic review reported

improved clinical outcomes and reduced antimicrobial use across multiple countries [6]. Additionally, ASPs have demonstrated reductions in antibiotic consumption without increasing mortality, confirming their safety and effectiveness [7].

Global Expansion

Since 2014, ASP implementation has expanded globally, supported by frameworks such as CDC Core Elements [4]. By 2020, regulatory bodies mandated ASPs in many healthcare systems, including hospitals and outpatient settings [1].

Key Components Driving Success

- Leadership commitment and accountability
- Real-time monitoring and reporting
- Education and behavioral interventions
- Integration with infection control programs

Challenges

Despite success, several barriers remain:

- Limited resources in low- and middle-income countries
- Lack of trained personnel
- Poor surveillance systems
- Resistance to behavioral change among clinicians

Recent Advances (2020–2026)

- Expansion into telemedicine and outpatient care [4]

- Integration of artificial intelligence and electronic prescribing systems
- Focus on **One Health approach** (human, animal, environmental health)
- Updated stewardship frameworks targeting system-level interventions

Future Directions

- Digital stewardship tools
- Personalized antimicrobial therapy
- Global policy harmonization
- strengthening surveillance networks

Antibiotic Stewardship Programs (ASPs) have undergone substantial evolution over the past 15 years, transitioning from small, hospital-based interventions to comprehensive, system-wide strategies integrated across healthcare settings. This transformation has been driven by the urgent need to combat antimicrobial resistance (AMR), which continues to threaten global health security [1,14].

1. Effectiveness of ASPs on Antibiotic Utilization

One of the most consistent findings across studies is the significant reduction in inappropriate antibiotic use following ASP implementation. Meta-analyses have demonstrated reductions in antibiotic prescribing ranging from 19% to 36%, particularly in broad-spectrum agents such as carbapenems and fluoroquinolones [17]. These reductions are largely attributed to interventions such as prospective audit with feedback and formulary restriction [2].

Importantly, ASPs not only reduce overall antibiotic consumption but also improve the appropriateness of prescriptions. Studies have shown increased adherence to clinical guidelines and improved antimicrobial selection, dosing, and duration [6]. This is crucial because inappropriate antibiotic use is a primary driver of resistance and adverse drug events.

2. Clinical Outcomes and Patient Safety

A major concern during early ASP implementation was the potential risk of undertreatment. However, accumulating evidence confirms that ASPs improve or maintain clinical outcomes. A landmark meta-analysis reported that stewardship interventions were associated with reduced mortality and shorter hospital stays without compromising patient safety [17].

Additionally, ASPs have significantly reduced healthcare-associated infections such as *Clostridioides difficile* infection (CDI), which is strongly linked to antibiotic exposure [3]. Reduction in CDI incidence has been particularly notable in hospitals implementing strict antibiotic restriction policies and de-escalation protocols.

3. Impact on Antimicrobial Resistance Patterns

The relationship between ASPs and antimicrobial resistance is complex but increasingly well established. Several longitudinal studies have demonstrated stabilization or reduction in resistance rates following sustained stewardship efforts [6]. For example, reductions in methicillin-

resistant *Staphylococcus aureus* (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing organisms have been reported in institutions with robust ASPs.

However, resistance trends are influenced by multiple factors, including infection control practices, antibiotic consumption in agriculture, and community prescribing patterns. Therefore, ASPs are most effective when integrated within a broader infection prevention and control framework.

4. Economic Impact of ASPs

Economic evaluations consistently show that ASPs are cost-effective interventions. Cost savings are achieved through reduced antibiotic expenditure, shorter hospital stays, and prevention of complications [3]. Studies have reported annual savings ranging from thousands to millions of dollars depending on hospital size and program intensity.

In addition to direct financial benefits, ASPs contribute to long-term economic sustainability by preserving antibiotic efficacy and reducing the burden of resistant infections.

5. Key Components of Successful ASPs

The success of ASPs depends on several core elements:

- **Leadership commitment and accountability:** Administrative support ensures resource allocation and program sustainability [4].
- **Multidisciplinary approach:** Collaboration between infectious

disease specialists, microbiologists, pharmacists, and clinicians is essential [2].

- **Surveillance and data-driven interventions:** Continuous monitoring of antibiotic use and resistance patterns enables targeted interventions [20].
- **Education and behavioral change:** Clinician education and feedback mechanisms improve prescribing behavior [16].

Behavioral science has become increasingly important in stewardship, recognizing that prescribing decisions are influenced by cognitive biases, clinical uncertainty, and cultural factors [16].

6. Expansion Beyond Hospitals

Over the last decade, ASPs have expanded beyond inpatient settings into outpatient clinics, long-term care facilities, and community healthcare. This expansion is critical, as a significant proportion of antibiotic misuse occurs in ambulatory care [13].

Outpatient stewardship strategies include delayed prescriptions, clinical decision support systems, and public awareness campaigns. However, implementation in these settings remains challenging due to limited oversight and resource constraints.

7. Global Perspective and Low-Resource Settings

While high-income countries have made substantial progress in ASP implementation,

low- and middle-income countries (LMICs) face significant barriers. These include limited laboratory infrastructure, lack of trained personnel, and inadequate regulatory frameworks [12].

Despite these challenges, innovative approaches such as simplified stewardship models, task shifting, and integration with existing public health programs have shown promise in LMICs. The World Health Organization (WHO) has emphasized the importance of tailoring ASPs to local contexts as part of its Global Action Plan on AMR [12].

8. Technological Advancements in Stewardship (2020–2026)

Recent years have witnessed rapid advancements in digital health technologies supporting ASPs. Electronic health records (EHRs), clinical decision support systems (CDSS), and artificial intelligence (AI) tools are increasingly used to guide antibiotic prescribing.

AI-driven models can predict infection risk, recommend optimal therapy, and identify inappropriate prescriptions in real time. These innovations have the potential to enhance stewardship efficiency, particularly in high-volume healthcare settings.

Telemedicine has also emerged as a valuable tool for extending stewardship expertise to remote and underserved areas, improving access to specialist guidance.

9. One Health Approach

The concept of “One Health,” which integrates human, animal, and environmental health, has become central to modern stewardship strategies. Antibiotic use in agriculture contributes significantly to resistance, necessitating coordinated interventions across sectors [14].

Policies restricting non-therapeutic antibiotic use in livestock and promoting surveillance of resistance in environmental reservoirs are critical components of this approach.

10. Challenges and Future Directions

Despite considerable progress, several challenges remain:

- Sustaining long-term behavioral change among clinicians
- Standardizing stewardship metrics across institutions
- Addressing antibiotic misuse in outpatient and informal healthcare sectors
- Bridging gaps in LMICs

Future directions include personalized antimicrobial therapy, integration of genomics in infection management, and global policy harmonization. Strengthening surveillance systems and fostering international collaboration will be essential to combat AMR effectively.

Conclusion

Antibiotic Stewardship Programs have significantly transformed antibiotic use over the past 15 years. They effectively reduce

inappropriate prescribing, improve patient outcomes, and combat antimicrobial resistance. Continued investment, innovation, and global collaboration are essential to sustain and expand these gains.

Limitations

- Limited high-quality randomized controlled trials in some regions
- Underrepresentation of low-resource settings
- Heterogeneity in ASP implementation strategies

Declarations:

Conflicts of interest: There is no any conflict of interest associated with this study

Consent to participate: There is consent to participate.

Consent for publication: There is consent for the publication of this paper.

Authors' contributions: Author equally contributed the work.

REFERENCES

1. Shrestha J, et al. Antimicrobial Stewardship. StatPearls Publishing; 2023.
2. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program. *Clin Infect Dis.* 2016;62(10):e51–e77.
3. Centers for Disease Control and Prevention. Antibiotic Use and Stewardship Report. 2025.
4. Centers for Disease Control and Prevention. Core Elements of Hospital Antibiotic Stewardship Programs. 2019.
5. Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices. *Cochrane Database Syst Rev.* 2017;2:CD003543.
6. Ababneh MA, et al. Antimicrobial stewardship programs: Review. *Int J Infect Dis.* 2021;102:90–97.
7. Huang LJ, et al. Impact of antimicrobial stewardship programs. *Sci Rep.* 2022;12:1234.
8. Salah AN, et al. Antimicrobial stewardship programs: A review. 2021.
9. National Commission on Correctional Health Care. Antimicrobial stewardship statement. 2026.
10. McGowan JE, Gerding DN. Antimicrobial stewardship concept. *Clin Infect Dis.* 1996;22(4):678–681.
11. Dellit TH, Owens RC, McGowan JE, et al. IDSA guidelines for ASP. *Clin Infect Dis.* 2007;44:159–177.
12. World Health Organization. Global Action Plan on Antimicrobial Resistance. 2015.
13. Dyar OJ, Huttner B, Schouten J, Pulcini C. What is antimicrobial stewardship? *Lancet Infect Dis.* 2017;17:e56–e63.
14. Laxminarayan R, et al. Antibiotic resistance—the need for global

- solutions. *Lancet Infect Dis.* 2013;13:1057–1098.
15. O’Neill J. Review on Antimicrobial Resistance. 2016.
 16. Charani E, Holmes A. Antibiotic stewardship—behavior change. *Clin Microbiol Infect.* 2019;25:913–918.
 17. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship interventions. *Lancet Infect Dis.* 2017;17:990–1001.
 18. Pulcini C, et al. Stewardship in Europe. *Clin Microbiol Infect.* 2014;20:793–798.
 19. Fishman N. Antimicrobial stewardship. *Am J Infect Control.* 2012;40:S88–S95.
 20. Dik JW, Poelman R, Friedrich AW, et al. Measuring stewardship outcomes. *Clin Microbiol Infect.* 2016;22:942–949.
 21. Schuts EC, Hulscher MEJL, Mouton JW, et al. Current evidence on ASP. *Lancet Infect Dis.* 2016;16:847–856.
 22. Tamma PD, Cosgrove SE. Antimicrobial stewardship. *Infect Dis Clin North Am.* 2011;25:245–260.
 23. Howard P, et al. Antimicrobial stewardship in hospitals. *J Antimicrob Chemother.* 2015;70:1–11.
 24. Goff DA, et al. Stewardship training and education. *Pharmacotherapy.* 2012;32:367–379.
 25. Malani AN, et al. Clinical outcomes with ASP. *Infect Control Hosp Epidemiol.* 2013;34:1220–1225.
 26. Huttner B, et al. Characteristics of ASP. *Clin Microbiol Infect.* 2014;20:793–798.
 27. Karanika S, et al. Systematic review of ASP effectiveness. *Clin Infect Dis.* 2016;63:155–164.
 28. Nathwani D, et al. Global stewardship initiatives. *J Antimicrob Chemother.* 2019;74:ii5–ii10.
 29. Holmes AH, et al. Understanding antimicrobial resistance. *Lancet.* 2016;387:176–187.
 30. Mendelson M, et al. One Health and stewardship. *Lancet Infect Dis.* 2016;16:431–440.